Adaptimmune Therapeutics PLC (ADAP)
0.9705
+0.07
(+8.03%)
USD |
NASDAQ |
Apr 19, 16:00
0.9705
0.00 (0.00%)
After-Hours: 18:48
Adaptimmune Therapeutics Net Income (Quarterly): -47.92M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -47.92M |
| September 30, 2023 | -45.60M |
| June 30, 2023 | -21.39M |
| March 31, 2023 | 1.036M |
| December 31, 2022 | -29.25M |
| September 30, 2022 | -41.42M |
| June 30, 2022 | -44.52M |
| March 31, 2022 | -50.26M |
| December 31, 2021 | -38.86M |
| September 30, 2021 | -42.40M |
| June 30, 2021 | -39.07M |
| March 31, 2021 | -37.76M |
| December 31, 2020 | -36.61M |
| September 30, 2020 | -35.43M |
| June 30, 2020 | -29.88M |
| March 31, 2020 | -28.17M |
| December 31, 2019 | -29.36M |
| September 30, 2019 | -39.30M |
| Date | Value |
|---|---|
| June 30, 2019 | -41.09M |
| March 31, 2019 | -27.41M |
| December 31, 2018 | -36.17M |
| September 30, 2018 | 5.242M |
| June 30, 2018 | -43.84M |
| March 31, 2018 | -21.08M |
| December 31, 2017 | -27.26M |
| September 30, 2017 | -0.878M |
| June 30, 2017 | -20.22M |
| March 31, 2017 | -21.78M |
| December 31, 2016 | -15.41M |
| September 30, 2016 | -18.49M |
| June 30, 2016 | -22.10M |
| March 31, 2016 | -15.58M |
| September 30, 2015 | -1.359M |
| December 31, 2014 | -1.592M |
| September 30, 2014 | -3.266M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-50.26M
Minimum
Mar 2022
1.036M
Maximum
Mar 2023
-35.65M
Average
-38.86M
Median
Dec 2021
Net Income (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | -9.507M |
| Autolus Therapeutics PLC | -77.17M |
| Mereo BioPharma Group PLC | -- |
| TC BioPharm (Holdings) PLC | -- |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.231M |
| Total Expenses (Quarterly) | 50.09M |
| EPS Diluted (Quarterly) | -0.18 |
| Enterprise Value | 74.81M |
| Profit Margin (Quarterly) | -20.74K% |
| Earnings Yield | -48.82% |
| Normalized Earnings Yield | -58.13 |